Phathom Pharmaceuticals
Brings Takeda's vonoprazan acid blocker to U.S. patients under the VOQUEZNA brand.
$9.45
Pre-market−0.12 (−1.20%)
At close$9.57(+4.19%)
Something off on this page? Send us feedback.
Next report
Oct 29, 2026
in 58 days
EPS estimate
$0.07
Revenue estimate
$85.4M
Fiscal quarter
Q3 FY26
EPSReportedEstimate
Mar '25May '25Aug '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported−$0.79−$1.07−$0.79−$0.15−$0.16−$0.37−$0.21Pending
Estimate−$1.29−$1.06−$0.76−$0.30−$0.32−$0.27−$0.18$0.07
Surprise+38.8%−0.9%−3.9%+50.0%+49.9%−37.0%−19.6%—
RevenueReportedEstimate
Mar '25May '25Aug '25Oct '25Feb '26Apr '26Jul '26Oct '26
Reported$29.7M$28.5M$39.5M$49.5M$57.6M$58.3M$74.3MPending
Estimate$29.0M$35.6M$46.8M$57.4M$57.2M$55.9M$73.2M$85.4M
Surprise+2.2%−20.0%−15.5%−13.8%+0.7%+4.3%+1.4%—
History
| Date | Estimate | Reported | Surprise |
|---|---|---|---|
| Oct 2026 | $0.07 | — | — |
| Jul 2026 | −$0.18 | −$0.21 | −19.6% |
| Apr 2026 | −$0.27 | −$0.37 | −37.0% |
| Feb 2026 | −$0.32 | −$0.16 | +49.9% |
| Oct 2025 | −$0.30 | −$0.15 | +50.0% |
The latest year is open to everyone — the 30 quarters behind it read with an account. Sign in | |||
| Aug 2025 | |||
| May 2025 | |||
| Mar 2025 | |||
| Nov 2024 | |||
| Aug 2024 | |||
| May 2024 | |||
| Mar 2024 | |||
| Nov 2023 | |||
| Aug 2023 | |||
| May 2023 | |||
| Feb 2023 | |||
| Nov 2022 | |||
| Aug 2022 | |||
| May 2022 | |||
| Mar 2022 | |||
| Nov 2021 | |||
| Aug 2021 | |||
| May 2021 | |||
| Mar 2021 | |||
| Nov 2020 | |||
| Aug 2020 | |||
| May 2020 | |||
| Mar 2020 | |||
| Nov 2019 | |||
| Oct 2019 | |||
| Mar 2019 | |||
| Dec 2018 | |||
| Sep 2018 | |||
| Jun 2018 | |||
| Mar 2018 | |||
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Reaction |
|---|---|---|---|---|---|---|---|
| Oct 29, 2026 | $0.07 | — | — | $85.4M | — | — | — |
| Jul 30, 2026 | −$0.18 | −$0.21 | −19.6% | $73.2M | $74.3M | +1.4% | −22.4% |
| Apr 30, 2026 | −$0.27 | −$0.37 | −37.0% | $55.9M | $58.3M | +4.3% | +7.2% |
| Feb 26, 2026 | −$0.32 | −$0.16 | +49.9% | $57.2M | $57.6M | +0.7% | −7.4% |
| Oct 30, 2025 | −$0.30 | −$0.15 | +50.0% | $57.4M | $49.5M | −13.8% | +1.8% |
The latest year is open to everyone — the 30 quarters behind it read with an account. Sign in | |||||||
| Aug 7, 2025 | |||||||
| May 1, 2025 | |||||||
| Mar 6, 2025 | |||||||
| Nov 7, 2024 | |||||||
| Aug 8, 2024 | |||||||
| May 9, 2024 | |||||||
| Mar 7, 2024 | |||||||
| Nov 9, 2023 | |||||||
| Aug 10, 2023 | |||||||
| May 10, 2023 | |||||||
| Feb 28, 2023 | |||||||
| Nov 8, 2022 | |||||||
| Aug 2, 2022 | |||||||
| May 10, 2022 | |||||||
| Mar 1, 2022 | |||||||
| Nov 8, 2021 | |||||||
| Aug 10, 2021 | |||||||
| May 11, 2021 | |||||||
| Mar 30, 2021 | |||||||
| Nov 10, 2020 | |||||||
| Aug 6, 2020 | |||||||
| May 12, 2020 | |||||||
| Mar 19, 2020 | |||||||
| Nov 25, 2019 | |||||||
| Oct 28, 2019 | |||||||
| Mar 31, 2019 | |||||||
| Dec 31, 2018 | |||||||
| Sep 30, 2018 | |||||||
| Jun 30, 2018 | |||||||
| Mar 31, 2018 | |||||||